Title

Cell & Gene Therapies State of the Industry Briefing
Monday
January
08
Don't miss your chance to attend the largest cell and gene therapies-focused annual event taking place during JP Morgan week.
San Francisco, CA

RSVP Today!
Don't miss your chance to attend the largest cell and gene therapies-focused annual event taking place during JP Morgan week! Join 500+ expected attendees and RSVP for this premier gathering of key stakeholders in the field. More details on the 2018 agenda and speaker list will be available soon so please check back.

Who Attends?
Over 500 of the cell and gene therapy field's top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector's recent advances and outlook for the industry in the coming year.

Event Details
Date: Monday, January 8, 2018

Time: 8:00am - 9:50am
Location:
Parc 55 San Francisco, A Hilton Hotel
55 Cyril Magnin St.
San Francisco, CA 94102

Live Webcast Available
Can't attend this year's Briefing in person? Visit this page on the morning of January 8 from 8-9:50am PT to view the program's live-streaming webcast. For those who can't tune in at that time, the full webcast will be available and posted to this site two weeks after the meeting.

Questions?
Please contact Laura Parsons at lparsons@alliancerm.org.

 

Watch the 2017 Program Webcast Below!

To see all three of the video options click on the horizontal bars in the upper left corner.

2017 Program Agenda
8:00am - 8:20am | Introduction & Industry Update
Robert Preti, Chairman, Alliance for Regenerative Medicine; President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences

8:20am – 9:05am | Cell Therapies: Essential Requirements for Near-term and Long-term Commercial Success
This session will address the primary issues cell therapy companies are facing in regards to commercialization and continuing momentum in the sector. Discussion topics will include manufacturing, scale-up, assay development, logistics and market access.
Robert Preti, Chairman, Alliance for Regenerative Medicine; President, PCT, A Caladrius Company; SVP, Manufacturing and Technical Operations, Caladrius Biosciences (moderator)
Thomas Farrell, President and CEO, Bellicum Pharmaceuticals
Manfred Rüdiger, CEO, Kiadis Pharma
Barbra Sasu, VP, Allogeneic CAR T Platform, Pfizer
Jeff Walsh, Chief Financial and Strategy Officer, bluebird bio

9:05am – 9:50am | The Gene Therapy Pipeline: Will Clinical and Regulatory Progress Match Patient and Investor Expectations?
This panel will closely examine the current gene therapy and gene editing pipelines and discuss expectations of technical and clinical progress over the next 3-5 years in the sector's leading disease indications.
Sarah Haecker Meeks, Chief Scientific Officer, Adjuvant Partners; Director, Technology Sections, Alliance for Regenerative Medicine (moderator)
Nessan Bermingham, CEO, President and Founder, Intellia Therapeutics
Chris Mason, Chief Science Officer, AvroBio
Matthew Patterson, President and CEO, Audentes Therapeutics

​9:50am | Program Close